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Abstract
Background: Uncontrolled disease activity in inflammatory diseases of the joints, skin and bowel leads to morbidity
and disability. Disease-modifying therapies are widely used to suppress this disease activity, but cost-coverage is
variable. For Treaty First Nations and Inuit people in Canada without alternative private or public health insurance,
cost-coverage for disease-modifying therapy is provided through Non-Insured Health Benefits (NIHB). Our objective
was to describe the prevalence and patterns of treatment with disease-modifying therapy for the NIHB claimant
population, and also examine adjuvant therapy (analgesics, non-steroidal anti-inflammatory drugs (NSAIDs),
corticosteroids) use.
Methods: Cases (n = 2512) were defined by ≥1 claim for a disease-modifying anti-rheumatic drug (DMARD) or
biologic between 1999 and 2012 in the NIHB pharmacy claim database. The proportion of the population
with claims for individual agents and drug classes annually was calculated to estimate annual incidence and
prevalence rates for use of disease-modifying therapy, and the prevalence of use of individual DMARDs,
biologics and adjuvants. Differences in the proportion accessing adjuvant therapies and median doses in
the 6 months following initiation of disease-modifying therapies was estimated.
Results: The incidence rate of treatment was calculated at an average of 127.5 cases per 100,000 population between
2001 and 2012, and the cumulative prevalence, accounting for patients lost to the database, increased and then
stabilized at 1.3 % in the last three years of the study. Annual dispensation of methotrexate, combination DMARD
therapy and biologic therapy approached 35 %, 19 %, and 10 % of the cohort respectively. A declining prevalence of
claims for acetaminophen (28 % to 15 %) and anti-inflammatories (73 % to 63 %) occurred from 2000 to 2012, however
corticosteroid (32 %) and opioid (65 %) dispensation remained stable. The proportion of patients with claims for
NSAIDs (69.9 % to 61.1 %, p = 0.002), oral corticosteroids (45.4 % to 33.6 %, p < 0.001) and parenteral corticosteroids
(16.2 % to 8.3 %, p = 0.002) decreased in the 6 months following biologic initiation.
Conclusions: The proportion of NIHB clients with active claims for disease-modifying therapy is lower than expected
based on existing epidemiologic knowledge of the prevalence of inflammatory conditions in the First Nations and Inuit
populations. These findings should be further explored in order to optimize treatment outcomes for NIHB claimants
with inflammatory disease.
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Background
Inflammatory diseases of the joints (e.g. rheumatoid
arthritis, spondyloarthropathies) [1], bowel (e.g. Crohn’s
Disease, ulcerative colitis) [2–4] and skin (e.g. psoriasis)
[5] are leading causes of disability in Canadian society.
These chronic conditions are characterized by immune-
mediated inflammation of their respective target organs,
along with systemic consequences that result in prema-
ture death. Although these diseases seem diverse and
can occur in isolation, their pathogeneses overlap [6, 7]
and they are treated with the same medications. Disease-
modifying anti-rheumatic drugs (DMARDs), such as
methotrexate, sulfasalazine, or leflunomide, inhibit syn-
thesis of deleterious inflammatory cytokines. Biologic ther-
apies, including anti-tumor necrosis factor α agents, B-cell
depletion and T-cell costimulation inhibition strategies,
block the activation or consequences of inflammatory
cascades that trigger clinical inflammation.
Epidemiology studies on the prevalence of inflammatory
conditions in the Indigenous peoples in Canada highlight
differences based on ancestry and disease. Rheumatoid
arthritis affects twice as many First Nations persons as
compared to non-First Nations [8], and the Haida popula-
tion of British Columbia has seven times the rate of anky-
losing spondylitis compared to the general population [9].
In contrast, inflammatory bowel diseases such as Crohn’s
disease and ulcerative colitis are considered rare in First
Nations populations [10], and rheumatoid arthritis was
not more common in Inuit populations [11]. To date,
no published studies have characterized psoriasis or
psoriatic arthritis prevalence or phenotype in any Indi-
genous groups. Inflammatory arthritis among First Na-
tions People is also more severe [12] and is associated
with worse disability [13] compared to non-First Nations.
Timely diagnosis and effective use of disease-modifying
therapy are proven strategies to reduce the impact of
disease, as summarized in Solomon et al. [14]. Beyond
logistical barriers [15], disempowering experiences with
the healthcare system [16] will decrease the likelihood of
early diagnosis and frequent re-evaluation of disease activ-
ity needed to secure the best outcomes. An additional
consideration is the ability to access medications, which
is different for First Nations and Inuit patients with
Treaty Status under the Indian Act compared to other
Canadians, with the federal government being respon-
sible for pharmaceutical drug cost-coverage through
the Non-Insured Health Benefits (NIHB) program, if
not otherwise available through private or provincial
plans [17]. All approved prescribers can initiate and re-
new prescriptions for DMARDs and adjuvant therapy
prescriptions for symptom relief (including acetamino-
phen, non-steroidal anti-inflammatory drugs (NSAIDs),
opioids and corticosteroids). Biologic therapies are limited
use benefits, with specific criteria for provision such as
requiring the prescriber to be a medical specialist, and the
patient having active disease despite the use of first-line
therapies. The aim of our study was to examine preva-
lence of use with DMARDS and biologics for patients
covered by the NIHB formulary by examining paid
claims. We also sought to describe concomitant dispen-
sation of adjuvant therapies. This information will con-
tribute to the understanding of the quality of care




The NIHB Program, administered by the First Nations and
Inuit Health Branch (FNIHB), provides financial coverage
for formulary prescription medications for registered First
Nations and recognized Inuit populations in Canada when
not covered by another private or public drug plan. A re-
cent estimate suggests that the national utilization rate for
NIHB is estimated at 62 %. Each individual has a unique
client identification number, and each claim for medication
paid for by NIHB is recorded in the database. Medication
class, therapeutic class, chemical name, and drug identifi-
cation number, as well as dose and strength of the medica-
tion, the date of dispensation, and quantity dispensed are
recorded. Alberta NIHB pharmacy claims only were ana-
lyzed in this study.
Population denominator
A migration-adjusted total eligible claimant population
residing in the province of Alberta is calculated on March
31 of each year and was provided by FNIHB.
Case definition
Cases were defined by at least 1 claim for either a DMARD
or Biologic at any time during the study period (January 1,
1999 to December 31, 2012). DMARDs included metho-
trexate, sulfasalazine, hydroxychloroquine, azathioprine,
cyclosporine, gold, and leflunomide, whereas biologics in-
cluded anakinra, infliximab, adalimumab, etanercept, goli-
mumab, certolizumab pegol, rituximab, tocilizumab, and
abatacept. To increase the specificity of the case definition
by identifying claimants most likely to have inflammatory
joint, skin or bowel disease, but limited by restricted abil-
ity to link to primary records or administrative data, we
excluded individuals who also received medications pri-
marily indicated to prevent transplant organ rejection
(tacrolimus, sirolimus, mycophenolate mofetil).
Claims analyzed
For individuals meeting the case definition, all DMARD,
biologic, analgesic (acetaminophen, opioids), NSAIDs and
corticosteroids (oral, injection) claims during the study
period were available for analysis.
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Incident cases
We applied a 2 year run-in period to define incident
cases, such that those individuals with claims for a
DMARD or biologic in fiscal years 1999/2000 and 2000/
2001 were considered to have prevalent disease, and
those individuals with no claims meeting the case defin-
ition in those years but subsequently meeting the case
definition were considered incident in the year of the
first claim.
Outcomes and statistical analysis
SAS (version 9.3) was used to analyze the following
outcomes:
i) Incidence and prevalence rates for treatment: The
cumulative prevalence rate for treatment, reported as
cases per 100 population, included individuals who met
the case definition and continued to have active claims
for a DMARD or biologic agent in each fiscal year;
cases were removed from the numerator if a fiscal
year lapsed with no claims for any of the agents of
interest. The incidence rate, reported as new cases
under treatment per 100,000 population, included
individuals meeting the case definition for the first
time in each fiscal year excluding the run-in period.
The denominator for both the cumulative prevalence
and the incidence rate was the migration-adjusted
population total registered in the province on
March 31 of that year, thus accounting for patients
lost to the database.
ii) Proportional distribution of use of DMARDs and/or
biologics in prevalent cases: In clients under active
treatment, the annual prevalence of drug use was
calculated for DMARDs and/or biologics as therapeutic
classes, as well as for individual agents in these classes,
by examining paid claims. The number of individuals
with at least one claim in each year of the database for
the agent of interest was used as the numerator, and
the denominator was the cohort of patients meeting
the case definition who remained prevalent in the
database.
iii) Prevalence of use of adjuvant therapies: The
proportion of the prevalent cases with claims for
acetaminophen, opioids, NSAIDs and/or corticosteroids
was calculated in each year of the database.
iv) Use of adjuvants prior to and following DMARD or
biologic initiation: To determine the effect of disease-
modifying therapy initiation on the need for adjuvant
therapy, we compared the prevalence of claims and
median daily dose of adjuvant agents as a class in the
six months prior to the prescription for a DMARD or
biologic, to a six month time period following the
dispensation of the first DMARD or biologic. For the
patients exclusively treated with DMARDs, we included
cases with a first claim for any therapeutic agent after
April 1, 2002. All the patients treated with biologic
therapies were considered incident cases and could be
included in this analysis, as the study period included
years prior to the availability of biologic therapies.
McNemar’s test was used to test for changes in the
prevalence of use during the two time periods,
whereas the comparison of median daily doses was
by Wilcoxon signed rank test. Median doses were
calculated from the dose of the medication, number
of doses supplied, and number of days supplied,
applying conversions of opioids to an oral morphine
equivalent (http://nationalpaincentre.mcmaster.ca/
opioid/cgop_b_app_b08.html), steroids to an oral
prednisone equivalent (http://www.globalrph.com/




Cohort of patients with inflammatory disease
A total of 2578 individuals received at least 1 claim for a
DMARD or biologic during the study period. After
applying exclusion criteria, 2512 individuals remained
for analysis, including 1853 females (73.8 %). A total of
217 individuals (8.6 %) entered the database at <18 years
of age, and most were under the age of 60 years at the
date of the first recorded claim (n = 2330; 92.8 %). The
majority of patients (n = 1658; 66.0 %) had their first
claim in the database in 1999, for a median of 12.8 (IQR
8.3–13.8) years of follow-up per person. The median
number of claims for the drugs of interest was 94.0 (IQR
30.0–243.0) per individual, and a total of 442,082 claims
were analyzed.
i) Incidence and prevalence rates for treatment: In 1999,
a total of 318 individuals had a claim for a DMARD,
increasing to 2512 ever-claimed during the study period
and with 1725 prevalent cases in 2012. The incidence
rate of treatment was calculated at an average of 127.5
cases per 100,000 population between 2001 and 2012,
with a peak in 2012 at a rate of 143.1 cases per 100,000
population (Fig. 1). During this same time the cumula-
tive prevalence, accounting for patients lost to the data-
base, increased and then stabilized at 1.3 % in the last
three years of the study.
ii) Proportional distribution of use of DMARDs and/or
biologics in prevalent cases: The proportion of patients
meeting the case definition and receiving at least one
claim in the fiscal year for individual DMARD agents is
depicted in Fig. 2. Methotrexate was used by 30 to
35 % of cases in each year, and combination DMARD
therapy by 11 to 19 % of cases in each year. The use of
sulfasalazine, azathioprine and leflunomide remained
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below 10 %, with negligible use of cyclosporine and
gold by 2012.
The first claim for a biologic agent was in 2002,
with a total of 266 individual users during the
study period. The prevalence of use in 2012 was
9.8 % (n = 169/1725). The majority of biologics
were used in combination with DMARDs
(ranging from 54 to 76 % in each year).
Etanercept was the most frequently claimed
biologic during the study period (n = 815/1149
claims; 70.9 %), followed by adalimumab
(n = 204/1149 claims; 17.8 %).
iii) Prevalence of use of adjuvant therapies: (Fig. 3):
A declining annual prevalence of claims for
acetaminophen (from 27.7 % in 2001 to 14.8 %
in 2012), and NSAIDs (from 73.3 % in 2001 to 62.9 %
in 2012) was observed. The proportion of patients
with corticosteroid and opioid claims was stable, with
Fig. 1 Incidence rate of initiation of DMARDs or biologic therapies in Alberta non-insured health benefits clients
Fig. 2 Prevalence of DMARD use by agent, 2001–2012
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an annual range of 31.3–37.7 % and 61.9–66.3 % of
patients respectively.
iv) Use of adjuvants prior to and following DMARD or
biologic initiation: A total of 456 individuals had
their first service date after 2002 and had claims
for DMARDs only, forming the cohort of incident
DMARD-treated cases. The prevalence of use of acet-
aminophen, NSAIDs, opioids and corticosteroids
in the 6 months prior to
and following DMARD initiation these cases is
shown in Table 1. The use of oral corticosteroids in-
creased in this incident cohort in the 6 months follow-
ing DMARD initiation compared to the 6 months
before, rising from 21.9 % to 31.1 %
(p < 0.001). Median doses of NSAIDs dispensed
were observed to increase as well (Table 2).
Biologics
Patients initiated on biologic therapy were prescribed a
median of 3 DMARDs before the biologic started. In the
six months after starting a biologic, the median number
of DMARDs maintained was 1 (p < 0.001, Wilcoxon sign
rank test). Furthermore, whereas 24 individuals did not
have a claim for a DMARD in the 6 months prior to bio-
logic start, this increased to 56 individuals in the 6 months
following a biologic start. A significant reduction in the
prevalence of use of NSAIDs and corticosteroids was seen
in the 6 months following the initiation of biologic ther-
apy. The proportion of cases with claims for NSAIDs
decreased from 69.9 % to 61.1 % (p = 0.002), as did the
proportion with claims for oral corticosteroids (45.4 % to
33.6 %, p < 0.001) and parenteral corticosteroids (16.2 % to
8.3 %, p = 0.002). However there was no difference in the
Fig. 3 Prevalence of use of adjuvant therapies
Table 1 Prevalence of use of adjuvant therapies for incident cases receiving DMARDs and individuals receiving biologics, 6 months
pre-post
Incident DMARD users (n = 456) Biologic users (n = 229)a









Acetaminophen 21 (4.6 %) 21 (4.6 %) 1.0000 29 (12.7 %) 27 (11.8 %) 0.8
NSAIDs 162 (35.5 %) 165 (36.2 %) 0.8682 160 (69.9 %) 140 (61.1 %) 0.002
Opioids 95 (20.8 %) 113 (24.8 %) 0.0918 154 (67.3 %) 147 (64.2 %) 0.2
Oral Steroids 100 (21.9 %) 142 (31.1 %) 0.0001 104 (45.4 %) 77 (33.6 %) <0.001
Parenteral Steroids 13 (2.9 %) 22 (4.8 %) 0.1221 37 (16.2 %) 19 (8.3 %) 0.002
aIncludes patients with data available for 6 months prior to and following biologic initiation
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proportion of cases with claims for acetaminophen and
opioids (Table 1). Median doses of opioids were observed
to increase, as did the median dose of corticosteroids for
those continuing to use them (Table 2).
Discussion
Our analysis presents data on the prevalence of accessing
medication cost-coverage for disease-modifying therapies
and adjuvant therapies by Treaty First Nations and Inuit
peoples in Alberta through the Non-Insured Health Bene-
fits Plan. Annually, approximately 1.3 % of the population
is accessing disease-modifying therapy through this pro-
gram. When placed in the context of underlying inflam-
matory disease prevalence, for which disease-modifying
therapy is indicated, this leads us to believe that it is likely
that many First Nations and Inuit in Alberta are not re-
ceiving pharmacotherapy for their conditions. Epidemi-
ology studies have estimated that rheumatoid arthritis
alone has a prevalence of nearly 1 % in the general
Canadian population [1], but is twice as high in the
predominantly Algonquin First Nations population of
Manitoba [8], and even higher in other tribal areas of
North America [18, 19]. In Alberta, our estimate of the
prevalence of rheumatoid arthritis in First Nations people
is 3.2 per 100 population, with the ankylosing spondylitis
rate at 0.6 per 100 population, and the psoriatic disease
(skin and/or arthritis) rate at 0.3 per 100 population [20].
Thus, while NIHB clients with inflammatory disease are
presenting for treatment as seen in the incidence rate for
treatment in this study, they are not being retained in care,
reflected in the low prevalence of claims for DMARDs
and biologics annually in relation to inflammatory disease
prevalence rates.
Our study also provides information on annual use of
individual DMARDs and biologic agents. Methotrexate
claims were made by 30 to 35 %, and biologic therapy
claims by 10 % of cases in our study annually. No direct
comparison of rates to the general population requiring
disease-modifying therapy is available. However, we expect
that our data largely reflects patients with rheumatoid
arthritis, due to it being the most common inflamma-
tory disorder for which DMARDs and biologics are
used. Methotrexate is the first-line therapy indicated for
rheumatoid arthritis, and was used by 72 % of patients in
a recently reported Canadian cross-sectional study [21];
estimates of rates of use of biologics for rheumatoid
arthritis from population-based administrative datasets in
Ontario was 23.5 % [22], similar to that in the Netherlands
(22 %) [23], or the United States (26 %) [24]. Thus, our
findings are counterintuitive given findings of worse
arthritis severity in First Nations people [12]. A reassur-
ing trend was the increased use of combination therap-
ies in recent years. By 2012, approximately 20 % of
DMARDs were used in combination, and the majority
of patients with claims for biologic therapies concomi-
tantly have claims for at least one DMARD, which im-
proves efficacy and survival of biologic agents. Prior to
our study, the only publication discussing therapeutic
exposures for DMARDs was for Aboriginal patients
with rheumatoid arthritis in Manitoba, who had more
DMARD, combination therapy and corticosteroid expo-
sures [12]. As the dataset used in our study does not
allow exploration of reasons for our observations at the in-
dividual level, we cannot identify specifically what factors
influence this perceived under-utilization of evidence-based
therapies. We can only hypothesize potential explanations,
such as medical contraindications to these agents, perceived
difficulties in monitoring for adverse events, or patient con-
cerns of toxicity. In addition to patient-specific reasons for
not proceeding with biologic therapy, an additional consid-
eration is that the low prevalence of use may reflect both
difficulties in accessing specialist care, a necessary criteria
of the NIHB formulary for a biologic prescription to be ap-
proved, as well as a multi-step process for limited use pre-
scription approvals and renewals. FNIHB and the Canadian
Rheumatology Association Optimal Care Committee have
Table 2 Comparison of median doses (interquartile range) in the six months prior to and six months after inflammatory disease
therapy initiation
Acetaminophen NSAIDsa Opioidsb Corticosteroidsc












































amg of ibuprofen equivalent
bmg of morphine equivalent
cmg of prednisone equivalent
dIncludes patients with data available for 6 months prior to and following biologic initiation
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been working collaboratively to streamline the clinical in-
formation requested from medical specialists, and improve
communication processes to ensure the physicians are
aware of the status of claims. As well, changes in the
NIHB formulary criteria effective March 2014 brings the
required DMARD trials before biologics for rheumatoid
arthritis patients in line with the current evidence-base.
We encourage further activities that eliminate process
inefficiencies and facilitate access to necessary therapies
that may be barriers to achieving optimal disease out-
comes for not only NIHB clients but all patients with
inflammatory disease.
The study of the use of adjuvant therapy contributes
to the understanding of management of symptoms of
inflammatory diseases for which disease-modifying ther-
apy is initiated. Although steroids are appropriate to
manage severe disease or flares for limited time periods,
their ongoing use and increasing dose indicates subopti-
mally treated disease, and places individuals at risk for
complications of diabetes, hypertension, cardiovascular
disease, infection, osteoporosis, glaucoma and cataracts.
We found that approximately one-third of NIHB clients
meeting the case definition were exposed to steroids during
their disease course. Although opioids may be prescribed
for other medical conditions, a high prevalence of use sug-
gests under-treatment of the primary condition and/or per-
manent joint damage from untreated inflammation. Here,
our results on the frequency of use of adjuvant therapies
once a biologic was initiated are helpful in demonstrating
the benefit of optimal treatment, as significant reductions
in the proportion of clients using anti-inflammatories and
both oral and parenteral corticosteroids occurred. This is
however tempered by the finding of increases in the median
doses of steroids and opioids in those continuing to receive
these therapies, likely reflecting clients with more severe or
refractory disease having persistent adjuvant therapy re-
quirements. Our treatment goals should continue to focus
on optimal treatment of inflammatory disease to reduce
potential complications arising from exposure to these
particular adjuvants.
Our study provides important information on treatment
patterns and has advantages in being population-based,
however we do acknowledge that the main limitation is
the lack of clinical data to confirm diagnosis and provide
information on disease severity or complications. We also
assumed that corticosteroids were used for disease
flares, although they may have been indicated for other
conditions, such as exacerbations of chronic obstructive
pulmonary disease or allergic reactions, and the entire
therapeutic history of individuals was not analyzed.
Population migration and delays in reporting of births
and deaths may affect our estimates, but the magnitude
of this error will be consistent throughout each annual
time period examined. As is expected in pharmacotherapy
studies, we were unable to confirm if the medication was
actually taken by the patient, and the dataset excludes
medications received in hospital, bought by individuals as
over-the-counter therapies, or through private/provincial
payment sources. We could not account for these nor
claims made in other provinces in our exposure-duration
assessment. Individual choices to not proceed with thera-
peutic recommendations may also factor in the observed
patterns of use. Further research would be necessary to
confirm our findings at the individual level and explore
why the trends were observed. Finally, we were unable to
stratify our analysis for First Nations and Inuit populations
separately, although a low proportion of the total Alberta
population is Inuit (<0.1 %) and we believe our data
largely represents NIHB clients of First Nations descent.
Separate studies to discover unique trends that may exist
for Inuit populations should be considered.
Conclusions
In summary, the proportion of NIHB clients with active
claims for disease-modifying therapy is lower than antici-
pated, with low prevalence of use of biologic therapies.
The rationale of these findings should be further explored
in order to increase the use of effective therapies. In
addition, health systems and providers need to re-evaluate
how they can provide high quality care and services that
actively engage Indigenous patients afflicted with inflam-
matory disease in care. The combination of changes in
health system policies and healthcare delivery offer the
opportunity to improve inflammatory disease outcomes
for Indigenous patients in Canada.
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